Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Treatments
    • Research
    • Safety
    • COVID-19
    • ONS Congress
    • Clinical practice
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    Zoom Through Video Job Interviews With These Tips for Applicants and Hiring Managers
    nursing professional development
    Zoom Through Video Job Interviews With These Tips for Applicants and Hiring Managers
    January 22, 2021
    The Case of Concurrent Therapy Concerns
    Treatment side effects
    The Case of Concurrent Therapy Concerns
    December 18, 2020
    In a World Where You Can Be Anything, Be Kind
    Nurse staffing
    In a World Where You Can Be Anything, Be Kind
    December 11, 2020
    Nursing Innovation Links Rural Facilities to Resources and Experts to Provide High-Quality Care Across the Country
    Access to cancer care
    Nursing Innovation Links Rural Facilities to Resources and Experts to Provide High-Quality Care Across the Country
    December 04, 2020
    Why All Oncology Nurses Should Be Environmentalists
    Oncology nurse influence
    Why All Oncology Nurses Should Be Environmentalists
    November 27, 2020
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
  • News & Views

    Clinical practice

    Cancer Rehabilitation Serves a Critical Role in Patient Care
    Prehabilitation

    Cancer Rehabilitation Serves a Critical Role in Patient Care

    More and more providers are recognizing that prehabilitation and rehabilitation are key components of successful patient-centered cancer care. Oncology nurses serve as a critical access point to those services and must understand rehabilitation and its indications. To better highlight cancer rehabilitation’s benefits and importance in clinical practice, ONS members Grace Campbell, PhD, MSW, RN, CNL, CRRN, and Beverly Reigle, PhD, RN, shared a conversation about the finer points of cancer rehabilitation specialty practice.

    October 11, 2019
    irAEs Linked to Improved Benefit From Pembrolizumab
    Immunotherapy

    irAEs Linked to Improved Benefit From Pembrolizumab

    Patients with advanced melanoma who received adjuvant therapy with pembrolizumab and subsequently developed immune-related adverse events (irAEs) saw a 63% reduced risk of recurrence, compared to 44% for those who did not develop irAEs. The study findings were presented at the 2019 American Society of Clinical Oncology annual meeting.

    October 09, 2019
    Patient Education Is Critical to Managing irAEs for Immune Checkpoint Inhibitors
    Immunotherapy

    Patient Education Is Critical to Managing irAEs for Immune Checkpoint Inhibitors

    By rebalancing the immune system and re-engaging mechanisms that tumor cells have shut off, immunotherapies such as immune checkpoint inhibitors enable patients’ own bodies to fight their cancers for them. But those same mechanisms can also result in immune-related adverse events (irAEs).

    October 08, 2019
    Complexity Is the Cornerstone of BMT Nursing
    Oncology nursing roles

    Complexity Is the Cornerstone of BMT Nursing

    You’re juggling three patients: one is nauseated and requesting lorazepam now, another’s blood transfusion is finished and the pump’s alarm is loudly chirping down the hall, the third has an order list coming in like rapid fire—and it’s only 8 am. In a blood and marrow transplant (BMT) unit, this sounds like a relatively calm morning.

    October 07, 2019
    What the Research Says About Drug Interactions and Medical Cannabis
    Oncology drug research

    What the Research Says About Drug Interactions and Medical Cannabis

    Despite medical cannabis’s legalization for medical use throughout 31 different jurisdictions in the United States, practicing providers have little research and few guidelines for patient care. To address the gap, in 2018 the National Council of State Boards of Nursing published Nursing Guidelines for Medical Marijuana, which provides general nursing education and guidance—yet doesn’t discuss drug interactions, specifically. To understand how medical cannabis affects concomitant pharmaceuticals, nurses must have a basic knowledge of the endocannabinoid system (ECS).  

    October 04, 2019
    Patient-Centered Care Through the Oncology Care Model
    Quality of care

    Patient-Centered Care Through the Oncology Care Model

    Better care. Smarter spending. Healthier people. Those are the three hallmark goals of the Oncology Care Model, a value-based payment system developed by the Centers for Medicare and Medicaid Service’s Center for Innovation.

    October 01, 2019
    FDA Rolls Out More New Indications for Existing Agents
    U.S. Food and Drug Administration (FDA)

    FDA Rolls Out More New Indications for Existing Agents

    Pembrolizumab, lenalidomide, and avelumab all received new treatment indications in spring 2019. Here’s what you need to know about dosing, adverse events, and other nursing considerations for these and other drugs that the U.S. Food and Drug Administration (FDA) approved from April–June 2019.

    September 25, 2019
    Oncology Drug Reference Sheet: Erdafitinib
    Treatments

    Oncology Drug Reference Sheet: Erdafitinib

    Erdafitinib (Balversa™) is the first targeted therapy that the U.S. Food and Drug Administration approved for treatment of metastatic bladder cancer. 

    September 24, 2019
    Company Recalls TPN Bags Because of Leak and Infection Risk
    Safety

    Company Recalls TPN Bags Because of Leak and Infection Risk

    Bags used to store and administer total parenteral nutrition (TPN) are being recalled because of leaks near the divider rod and channel when the rod is removed, the Metrix Company of Dubuque, IA, announced on September 9, 2019.

    September 10, 2019
    Why Aren’t Nurses Adhering to PPE Requirements?
    Safety

    Why Aren’t Nurses Adhering to PPE Requirements?

    Oncology nurses are dedicated to providing the best, safest cancer care to their patients—protecting them from medical harm and prolonging life. But when it comes to protecting themselves, nurses sometimes take shortcuts in wearing personal protective equipment (PPE) that guards them against exposure to hazardous drugs. 

    September 10, 2019
    Handle With Care: How USP <800> Will Affect Nursing Practice
    Safe handling

    Handle With Care: How USP <800> Will Affect Nursing Practice

    Police officers wear body armor and construction workers wear hard hats. Why? Because these professions carry inherent dangers in the line of duty­—and oncology nursing does too. Statistically, healthcare workers face more workplace-related dangers than both law enforcement and construction, yet attention to safety and personal protection isn’t always a central focus. This can be especially true in cancer care, where nurses are required to administer hazardous drugs (HDs) and handle dangerous medications on a daily basis. Although safety recommendations exist, few enforceable standards are protecting nurses handling HDs.

    September 03, 2019
    To Prevent Hepatoxicity, Monitor Liver Function During Cancer Treatment
    Advanced practice nursing (APN)

    To Prevent Hepatoxicity, Monitor Liver Function During Cancer Treatment

    Because the liver is the primary site of metabolism for many drugs, baseline function testing and monitoring during cancer treatment are essential. However, the cause of an abnormal liver function test when a patient is receiving chemotherapy or immunotherapy can be difficult to determine. 

    August 28, 2019
    Oncology Drug Reference Sheet: Venetoclax
    Treatments

    Oncology Drug Reference Sheet: Venetoclax

    Venetoclax (Venclexta®) was approved by the U.S. Food and Drug Administration on May 15, 2019, for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) as a single agent or in combination therapy. Previously, it had been approved in late 2018 for use in combination therapy for acute myeloid leukemia (AML) in older adults or those with significant comorbidities.

    August 27, 2019
    The Case of the Safety Session
    Safety

    The Case of the Safety Session

    Doug is a 48-year-old triathlete who was recently diagnosed with chronic myeloid leukemia (CML) after a routine blood test showed an increase in white blood cells and a subsequent bone marrow biopsy showed greater than 20% blast cells. The medical oncologist prescribed the oral drug dasatinib. Doug and his wife meet with Staci, RN, to receive oral therapy education. During the teaching, Doug says his wife will have no trouble dispensing the dasatinib because she already prepares all of their meals and nutritional supplements.  

    August 20, 2019
    Clinical Trial Participants Average  6.5 Years Younger Than Actual Cancer Populations
    Research

    Clinical Trial Participants Average 6.5 Years Younger Than Actual Cancer Populations

    For the four most common cancer sites (breast, prostate, colorectal, and lung cancer), the median age of patients in clinical trials is an average of 6.5 years younger than the median age of patients diagnosed with that cancer. And the age disparity is worsening, researchers reported in JAMA Oncology. 

    August 07, 2019
    How Does ONS Support Nurses Who Care for Older Adults With Cancer?
    Clinical practice

    How Does ONS Support Nurses Who Care for Older Adults With Cancer?

    By bringing together gero-oncology experts from the ONS membership, staff, and leadership, the ONS geriatric oncology group is identifying gaps in geriatric oncology nursing research and care and connecting ONS members with available resources targeting this vulnerable population. Adult patients with cancer—aged 65 and older—already make up a majority of patients that oncology nurses see. Despite the population’s prevalence throughout cancer institutions and clinics, many nurses are not acutely familiar with the specialized care required to successfully help them navigate their treatment.  
     

    August 06, 2019
    Older Adults With Cancer
    Clinical practice

    Older Adults With Cancer

    The Baby Boomer generation—born between the years 1946 and 1964—currently accounts for more than 76 million Americans, all of whom will be older than 65 in the next decade. With an aging population comes health complications and growing comorbidities. Cancer is often referred to as a disease of the aging, and healthcare providers will need to be equipped to treat the impending wave of older adults with cancer. Oncology nurses are at the frontlines of that care and play a key role in the successful treatment of older patients with cancer using evidence-based interventions and age-specific care. 
     

    August 06, 2019
    The Case of the Pregnancy Predicament
    Clinical practice

    The Case of the Pregnancy Predicament

    A 33-year-old woman presents to the emergency department with fever, weight loss, and dyspnea. She is five months pregnant. A computed tomography (CT) chest scan without contrast shows a large mediastinal mass. Biopsy demonstrates Hodgkin lymphoma (HL), but magnetic resonance imaging (MRI) of her abdomen and pelvis without contrast is negative for lymphadenopathy. Her echocardiogram and pulmonary function testing are normal.

    August 02, 2019
    Sex Is an Important Dimension of Cancer Psychosocial Care That We Need to Stop Neglecting
    Sexual/reproductive issues

    Sex Is an Important Dimension of Cancer Psychosocial Care That We Need to Stop Neglecting

    My charge nurse approached me and told me that I am getting an admission from the emergency department who presented with high blood pressure and shortness of breath. She told me that the patient is on concurrent chemoradiation therapy and has a rectal cancer.

    July 26, 2019
    FDA Recalls Textured Breast Implants Because of Lymphoma Risk
    U.S. Food and Drug Administration (FDA)

    FDA Recalls Textured Breast Implants Because of Lymphoma Risk

    On July 24, 2019, the U.S Food and Drug Administration (FDA) requested that Allergan recall its BIOCELL textured breast implants and tissue expanders because of the associated increased risk of breast implant-associated anaplastic large cell lymphoma; Allergan agreed and is removing the products from the global market.

    July 24, 2019
    Fitzpatrick Classification System
    Cancer risk prevention

    The Fitzpatrick Classification System Determines How Much UV Protection Is Needed to Prevent Sun Exposure

    The Fitzpatrick Classification System Determines How Much UV Protection Is Needed to Prevent Sun Exposure

    True or False?

    July 22, 2019
    High Fitness Linked to Lower Risk and Mortality in Lung and Colorectal Cancers
    Research

    High Fitness Linked to Lower Risk and Mortality in Lung and Colorectal Cancers

    Adults with the highest cardiorespiratory fitness levels have a reduced risk for lung and colorectal cancer—and a lower risk of death if they do develop the cancers, according to findings from a study published in Cancer.

    July 17, 2019
    The Case of the Explicit Exposure
    Clinical practice

    The Case of the Explicit Exposure

    Mr. Larsen presents to the clinic for his first dose of R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone) for a diagnosis of diffuse large B-cell lymphoma. Elizabeth, his oncology nurse, just started the cyclophosphamide when she is paged to the desk for a call from Mr. Larsen’s oncologist. She quickly removes her face shield and gloves as she hurriedly leaves the room to take the call. After completing the call, she returns to Mr. Larsen’s room to remove her gown.  

    July 16, 2019
    Which Tumor Marker Can Be Used to Assess Stage, Prognosis, Response to Treatment?
    Clinical practice

    Which Tumor Marker Can Be Used to Assess Stage, Prognosis, Response to Treatment?

    Which tumor marker can be used to assess stage, prognosis, response to treatment in germ cell tumors, lymphoma, melanoma, acute leukemia, and neuroblastoma?

    A. Programmed death ligand 1 (PD-L1)

    B. HE4

    C. Cytokeratin fragment 21-1

    D. Lactate dehydrogenase

    July 12, 2019
    How to Prepare for a Career in Oncology Nursing
    Nurse staffing

    How to Prepare for a Career in Oncology Nursing

    Oncology care is one of the most challenging, yet rewarding, nursing careers that offers opportunities to care for patients in all stages of life. It’s a chance to help guide and support your patients through one of the most difficult times in their lives and be inspired by their determination, hope, and faith.

    July 10, 2019
    Telehealth Programs Improve Symptom Management at Home
    Clinical practice

    Telehealth Programs Improve Symptom Management at Home

    July 09, 2019
    Collaboration Is Key to CAR T-Cell Therapy Management Across Settings
    Immunotherapy

    Collaboration Is Key to CAR T-Cell Therapy Management Across Settings

    As of February 2019, only 160 institutions across the United States are certified to administer CAR T-cell therapy, meaning many eligible patients may need to be referred to a treatment center outside of the local ambulatory or community cancer center where they had previously received treatment. The transition from primary oncologist to certified center and back again requires careful coordination to ensure important steps and information aren’t lost.

    July 09, 2019
    The Work We Do Now Affects Healthcare’s Future
    Nurse empowerment

    The Work We Do Now Affects Health Care’s Future

    The World Health Organization designated 2020 internationally as the Year of the Nurse and Midwife in honor of Florence Nightingale’s 200th birthday. To celebrate the work that nurses do globally, nursing organizations around the world are creating programs that offer recognition—as well as education, training, and professional development.

    July 08, 2019
    FDA Grants Accelerated Approval to Selinexor for Multiple Myeloma
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Selinexor for Multiple Myeloma

    On July 3, 2019, the U.S. Food and Drug Administration (FDA) granted accelerated approval to selinexor (XpvioTM) in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.

    July 03, 2019
    No Place Like It: Home Care for Patients With Cancer
    Clinical practice

    No Place Like It: Home Care for Patients With Cancer

    It’s more than just four walls and a roof. Home is where most people find comfort, solace, and a sense of familiarity. It’s where the heart is, and there’s no place like it. With advancements in cancer therapies, treatment care modalities, and technology, many of today’s patients are finding they can receive a large portion of their care in the home. Home care is not a new concept—rather it’s likely the oldest healthcare setting in human history—but it can be a complex and intricate care environment, especially when addressing specific needs related to cancer treatment. At its heart are expert oncology nursing professionals who safely deliver the best possible care for their patients—in the comfort of their own homes.  

    July 02, 2019
    FDA’s Latest Approved Drugs and Indications Include Two Oral Agents
    U.S. Food and Drug Administration (FDA)

    FDA’s Latest Approved Drugs and Indications Include Two Oral Agents

    Because two oral therapies received new indications in the U.S. Food and Drug Administration’s (FDA’s) most recent round of approvals, oncology nurses will want to focus on ways to manage patients in the home. Assessing oral adherence, encouraging patients to report adverse events, and ensuring their understanding of complex dosing regimens are critical components of nursing care. ONS offers an oral adherence toolkit and oral chemotherapy patient education sheets to help with patient management. 

    June 25, 2019
    Combination Trastuzumab  and Hyaluronidase-Oysk
    Treatments

    Oncology Drug Reference Sheet: Combination Trastuzumab and Hyaluronidase-Oysk

    A new product that combines trastuzumab and hyaluronidase (Herceptin Hylecta™) received U.S. Food and Drug Administration approval in February 2019 for the treatment of HER2-overexpressing breast cancer. The approval was based on the results of two randomized trials: HannaH and SafeHER. 

    June 18, 2019
    FDA Links Breast Implants to Increased ALCL Risk
    U.S. Food and Drug Administration (FDA)

    FDA Links Breast Implants to Increased ALCL Risk

    People with breast implants have a risk of developing breast implant-associated anaplastic large cell lymphoma (ALCL), the U.S. Food and Drug Administration (FDA) announced in April 2019. Typically the cancer is limited to the scar tissue and fluid near an implant, but some patients experience spread throughout the body. The risk increases with textured implants in particular.

    June 12, 2019
    Survivorship Considerations After CAR T-Cell Therapy
    Immunotherapy

    Survivorship Considerations After CAR T-Cell Therapy

    As more patients receive treatment with chimeric antigen receptor (CAR) T-cell therapy, oncology nurses will need to be aware of the long-term effects of treatment that may persist into survivorship. However, because the treatment is so new, studies measuring those patient-reported concerns are still forthcoming. The majority of today’s recommendations for survivorship management are based on experts’ clinical experience.

    June 11, 2019
    Nurses Are Crucial to Developing Tools, Best Practices for Novel Therapies
    Oncology nurse researcher

    Nurses Are Crucial to Developing Tools, Best Practices for Novel Therapies

    Advanced practice RNs (APRNs), especially those with Doctorate of Nursing Practice degrees, in clinics across the country must not only focus on managing care for patients on novel therapies like immunotherapy but must also look at toxicities and adverse events from a population perspective. APRNs should look across all patients and disease types receiving the same novel treatments and recognize toxicity patterns to determine best practices for patient management. 

    June 04, 2019
    Novel Therapies: How CAR T Cells and Biosimilars Are Changing Cancer Care
    Immunotherapy

    Novel Therapies: How CAR T Cells and Biosimilars Are Changing Cancer Care

    Clinical practice is in a constant state of evolution as new guidelines are released, drugs are approved for new indications, and technology reshapes the way care is delivered. Patients are also arming themselves with a more-advanced-than-ever knowledge and understanding of health care, and providers may be fielding new questions from patients and caregivers about novel treatments such as chimeric antigen receptor (CAR) T-cell therapy and biosimilars. 

    June 04, 2019
    FDA Updates REMS and Black Box Warnings for Blinatumomab
    U.S. Food and Drug Administration (FDA)

    FDA Updates REMS and Black Box Warnings for Blinatumomab

    In May 2019, the U.S. Food and Drug Administration (FDA) added new clarifications to its risk evaluation and mitigation strategy and black box warnings for blinatumomab (Blincyto®). Blinatumomab is a bispecific, CD19-directed CD3 T-cell engager indicated for the treatment of adults and children with (a) B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease greater than or equal to 0.1% or (b) relapsed or refractory B-cell precursor ALL.

    May 30, 2019
    FDA Approves Lenalidomide for Follicular and Marginal Zone Lymphoma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Lenalidomide for Follicular and Marginal Zone Lymphoma

    On May 28, 2019, the U.S. Food and Drug Administration (FDA) approved lenalidomide (Revlimid®) in combination with a rituximab product for previously treated follicular lymphoma and previously treated marginal zone lymphoma.

    May 29, 2019
    FDA Cautions That Robotic Devices Are Not Approved for Mastectomy or Other Women’s Cancer Surgeries
    U.S. Food and Drug Administration (FDA)

    FDA Cautions That Robotic Devices Are Not Approved for Mastectomy or Other Women’s Cancer Surgeries

    Because of limited preliminary evidence that the use of robotic-assisted surgical devices for treatment or prevention of women’s cancers may be associated with diminished long-term survival, the U.S. Food and Drug Administration (FDA) issued a reminder warning to healthcare providers and the public in February 2019 that the technique has not been FDA approved for this purpose.

    May 22, 2019
    Commission on Cancer to Revise Standards for Cancer Program Accreditation
    Standards

    Commission on Cancer to Revise Standards for Cancer Program Accreditation

    The Commission on Cancer (CoC), an organizational consortium of which ONS is a governing member, provides standards for cancer programs to follow to achieve a high level of continuous quality improvement. Last updated in 2016, the standards are currently undergoing analysis and revision, and CoC is seeking public comments until June 3, 2019.

    May 20, 2019
    FDA Approves Venetoclax for CLL and SLL
    U.S. Food and Drug Administration (FDA)

    FDA Approves Venetoclax for CLL and SLL

    On May 15, 2019, the U.S. Food and Drug Administration (FDA) approved venetoclax (Venclexta®) for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

    May 15, 2019
    FDA Approves Avelumab Plus Axitinib for Renal Cell Carcinoma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Avelumab Plus Axitinib for Renal Cell Carcinoma

    On May 14, 2019, the U.S. Food and Drug Administration (FDA) approved avelumab (Bavencio®) in combination with axitinib for first-line treatment of patients with advanced renal cell carcinoma.

    May 14, 2019
    The Case of the Terrible Toxicities
    Adverse events

    The Case of the Terrible Toxicities

    After completing neoadjuvant chemotherapy for triple-negative invasive breast cancer, Madeline, age 32, had a bilateral mastectomy with reconstructive surgery. Final pathology showed residual disease in the breast and one lymph node, and her oncologist recommended adjuvant therapy with capecitabine (1,500 mg twice a day for 14 days, off for 7 days). Five weeks postoperatively, she started cycle 1. Eight days later, her husband called the cancer clinic reporting that over the past two days, his wife developed profound weakness, unremitting diarrhea despite using diphenoxylate and atropine as directed, and painful, red, swollen hands and feet. Her symptoms represented a drastic change from her usual routine and energy level.

    May 14, 2019
    Liquid Biopsy Equivalent to Tissue for NSCLC
    Lung Cancer

    Liquid Biopsy Equivalent to Tissue for NSCLC

    With faster and equally accurate results, liquid biopsy may be an option for identifying guideline-recommended targeted therapies for non-small cell lung cancer (NSCLC), according to findings presented at the 2019 American Association for Cancer Research Annual Meeting in Atlanta, GA. 

    May 08, 2019
    FDA Approves Ivosidenib as First-Line Treatment for AML With IDH1 Mutation
    U.S. Food and Drug Administration (FDA)

    FDA Approves Ivosidenib as First-Line Treatment for AML With IDH1 Mutation

    On May 2, 2019, the U.S. Food and Drug Administration (FDA) approved ivosidenib (Tibsovo®) for newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, in patients who are at least 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy.

    May 03, 2019
    Stay Up to Date on Clinical Treatments for Metastatic CRC
    Advanced practice nursing (APN)

    Stay Up to Date on Clinical Treatments for Metastatic CRC

    Metastatic colorectal cancer (CRC) remains a significant health problem as the second leading cause of cancer death in the United States and the fourth most frequently diagnosed cancer. Despite improvements in some age groups, its incidence has actually been increasing in patients younger than 50 years. The cause of this trend is currently unknown.   

    May 02, 2019
    The Value of Oncology Nurse Certification
    Oncology nurse education

    The Value of Oncology Nurse Certification

    Oncology care is a complex field in a constant state of paradigm shifts, where new information and research affect clinical practice in countless ways. Amid rapid developments in treatments, technologies, and patient-care modalities, oncology nurses must show they’re up to date with emerging knowledge in their field. Oncology nurse certification is one way nurses can demonstrate their commitment to the art and science of patient-centered oncology care.

    May 01, 2019
    Updated Scope and Standards Represent Key Foci of Oncology Nursing Practice
    Clinical practice

    Updated Scope and Standards Represent Key Foci of Oncology Nursing Practice

    To ensure that the Oncology Nursing: Scope and Standards of Practice are consistent with overall nursing standards and to increase the visibility of the oncology nursing standards in the greater nursing and healthcare communities, ONS released an updated version of its reference book in March 2019. The American Nurses Association (ANA) recognizes oncology nursing as a nursing specialty, and the new edition carries ANA’s approval of the oncology nursing scope of practice and acknowledgement of the oncology nursing standards of practice.

    April 26, 2019
    How APRNs Can Manage Immunotherapy-Related Hypophysitis in Patients With Cancer
    Advanced practice nursing (APN)

    How APRNs Can Manage Immunotherapy-Related Hypophysitis in Patients With Cancer

    Immunotherapy may place patients at risk for distinctive toxicities that differ from traditional chemotherapy. One example is endocrine dysfunction, including hypophysitis, hypo- or hyperthyroidism, type 1 diabetes, and primary adrenal insufficiency. 

    April 25, 2019
    Self-Care for the Soles
    Nurse self-care

    Self-Care for the Soles

    The twenty-six bones in the foot are always being stepped on. Getting on one’s nerves takes on a whole new meaning when considering that each foot contains an estimated 200,000 nerve endings. With health enthusiasts recommending 10,000 steps per day, which translates to approximately five miles, is it any wonder that the often-abused soles deserve a little self-care? 

    April 23, 2019
    • First page « First
    • Previous page
    • Page 1
    • Page 2
    • Page 3
    • Current page 4
    • Page 5
    • Page 6
    • Page 7
    • Page 8
    • Page 9
    • …
    • Next page
    • Last page Last »
    Trending Topics
    • Treatments
    • Research
    • Safety
    • COVID-19
    • ONS Congress
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    • Health Policy
    • Immunotherapy
    • Oncology nurse influence
    View All Topics
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2021 Oncology Nursing Society
     
    Back to Top ▲